OnKure Therapeutics Q2 FY26 net loss narrows to $15.35 million; loss per share improves to $0.31
OKUR•Pipeline update
IND-enabling work continues for PI3Kα pan-mutant selective candidates OKI-345 and OKI-355, with IND submissions planned for 1H 2027.
Expenses and cash position
R&D spending was flat at $12.61 million; G&A costs rose to $4.29 million.
Cash, cash equivalents and marketable securities climbed to $176.39 million as of June 30, 2026, with runway expected into 2029.
Q2 net loss and per-share loss improve
OnKure Therapeutics posted a Q2 net loss of $15.35 million, narrowing from $15.39 million a year earlier; loss per share improved to $0.31 from $1.14.
